ProfileGDS5678 / 1435162_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 34% 34% 35% 35% 34% 41% 34% 33% 33% 34% 35% 37% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9361239
GSM967853U87-EV human glioblastoma xenograft - Control 22.7764734
GSM967854U87-EV human glioblastoma xenograft - Control 32.7823734
GSM967855U87-EV human glioblastoma xenograft - Control 42.7422635
GSM967856U87-EV human glioblastoma xenograft - Control 52.7431435
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8426634
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0069941
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7694134
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7362333
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7386533
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7714534
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7646835
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8456637
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7685634